E. Alsaleh et al., CISPLATIN ETOPOSIDE CHEMOTHERAPY FOR RECURRENT OR PRIMARILY ADVANCED CERVICAL-CARCINOMA/, Gynecologic oncology, 64(3), 1997, pp. 468-472
Thirty-eight women with primarily advanced (n = 10) or recurrent (n =
25) cervical carcinoma were treated with cisplatin (30 mg/m(2)/day int
ravenously) and etoposide (60 mg/m(2)/day intravenously) for 3 days fo
llowed by oral etoposide, 50 mg daily for 7 days, repeated at 28-day i
ntervals, The response rate was 39% (95% confidence limits 24-55%) wit
h response duration of 5 to 36 months. The main toxicities were neutro
penia (21% developing neutropenic fever), alopecia, stomatitis, and na
usea and vomiting, Despite this all responders had maintained or impro
ved quality of life as defined by symptoms and performance, status. (C
) 1997 Academic Press.